VolitionRx Limited (VNRX) is a publicly traded Healthcare sector company. As of May 21, 2026, VNRX trades at $2.34 with a market cap of $18.44M and a P/E ratio of 0.00. VNRX moved +5.53% today. Year to date, VNRX is -55.55%; over the trailing twelve months it is -74.64%. Its 52-week range spans $1.91 to $18.80. Analyst consensus is buy with an average price target of $40.00. Rallies surfaces VNRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
VolitionRx Targets $5M Milestone with 97% Specificity Feline Cancer Test: VolitionRx has submitted a clinical manuscript for its Nu.Q® Vet Feline prototype assay, which detected 86% of feline lymphomas at 97% specificity. Publication is expected to unlock a $5 million milestone payment and pave the way for commercial launch to tap a market of over 73.8 million US cats.
| Metric | Value |
|---|---|
| Price | $2.34 |
| Market Cap | $18.44M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.80 |
| 52-Week Low | $1.91 |
| Volume | 1.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.47M |
| Net Income | $-24.73M |
| Gross Margin | 0.00% |
3 analysts cover VNRX: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $40.00.